CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides

What happened

CDT Equity welcomed a U.S. regulatory change for compounded peptides, which it says supports its investment in Pep’d Inc. HHS announced a temporary policy of not enforcing action against qualifying state-licensed pharmacies, federal facilities, or licensed physicians compounding six named peptides while the FDA continues its rulemaking.

Confirmed

Global impact / market context

The policy could widen the legal room for pharmacies and doctors to prepare and prescribe these peptides, which may increase Pep’d’s addressable business and support CDT’s investment case. The relief is temporary and conditional, so revenue and demand benefits depend on patients, prescribers, and compliance with the stated requirements.

Analyst inference

CDT is a small company whose value is tied to a private peptide and telehealth investment, so this regulatory signal matters more than broad market moves. Enforcement discretion, meaning regulators choosing not to act against qualifying parties, reduces near-term legal risk but does not permanently legalize the peptides.

Analyst inference

What to watch

1. Watch whether the FDA completes its rulemaking on the Section 503A Bulks List, because the current HHS policy is interim and tied to that continuing process. Confirmed
2. CDT could disclose how Pep’d Inc. benefits, such as pharmacy partnerships, prescriber adoption, or revenue growth, since the company said the policy supports its investment. Proposed
3. Track whether qualifying pharmacies and physicians actually compound the six named peptides under the policy conditions, because real prescribing volume would be the clearest signal of commercial impact. Analyst inference

Evidence

• globenewswire.com